Broncus Holding Posts Narrowed Loss, Gains Market Ground

Broncus Holding Corp. (HK:2216) has released an update.

Broncus Holding Corp. reports a significant 46% reduction in net loss for the first half of 2024 compared to the previous year, due to cost optimizations in production and R&D. The company is making strides in the Chinese market with its lung disease surgery consumables, as its products gain traction in hospitals across the country. Notably, the InterVapor Thermal Vapor Treatment System is widely recognized for its effectiveness and is now commercially used in over 60 hospitals in China.

For further insights into HK:2216 stock, check out TipRanks’ Stock Analysis page.